Granulocyte colony-stimulating factor, granulocyte–macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients

Page, Andrea V.; Liles, W. Conrad

doi:10.1097/mot.0b013e3283186b80

Cited by 13 publications

(12 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,9,15,16 Following administration of mean 2.1 ± 1.9 doses of G-CSF, we observed WBC count recovery in median 9 (IQR 4-14) days, which is longer than previously reported in the literature. 2,4,8,13 Similar to the findings of Zafrani et al 2 , we did not observe differences in time to WBC count recovery in patients with therapy delays or those who never received a dose of G-CSF. Furthermore, we defined study inclusion based on leukopenia (WBC < 3000 cells/μL), 1,3,6,16 but all patients with available ANC data were neutropenic (ANC < 1000 cells/μL) at the time of G-CSF initiation.…”

Section: Ofsupporting

confidence: 88%

Single‐center, real‐world experience with granulocyte colony‐stimulating factor for management of leukopenia following kidney transplantation

Hamel

Kuo

Sawinski

et al. 2019

Clinical Transplantation

View full text Add to dashboard Cite

Background Leukopenia is a frequent complication following kidney transplantation. Granulocyte colony‐stimulating factor (G‐CSF) has been used to accelerate white blood cell (WBC) count recovery; however, published experience in kidney transplantation is limited. Methods We retrospectively reviewed our kidney transplant recipients from January 2012 to September 2016 with a G‐CSF order to evaluate leukopenia management (defined as WBC <3000 cells/μL). Results Thirty‐six recipients were included. On average, G‐CSF treatment began at 98 ± 38 days. At G‐CSF initiation, mean WBC count was 1240 ± 420 cells/μL and absolute neutrophil count (ANC) was 653 ± 368 cells/μL. Mean G‐CSF dose was 4.6 ± 1.2 mcg/kg/dose (total 11.8 ± 9.0 mcg/kg), 77.8% of recipients were prescribed G‐CSF as outpatients, and overall, median time to WBC count recovery was 9 (IQR 4‐14) days. Changes in immunosuppression and prophylaxis regimens for leukopenia were also common. Within 1 month following leukopenia onset, no patients experienced acute rejection and 5 (14%) developed infection requiring hospitalization or opportunistic infection. Conclusion In kidney recipients with leukopenia, G‐CSF may be helpful to achieve WBC count recovery in addition to changes in immunosuppression and prophylaxis medications. Prospective, randomized data are still needed to determine optimal G‐CSF dosing in this population.

show abstract

Section: Ofsupporting

confidence: 88%

Single‐center, real‐world experience with granulocyte colony‐stimulating factor for management of leukopenia following kidney transplantation

Hamel

Kuo

Sawinski

et al. 2019

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…We have shown that the use of stem cell mobilization agents, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), resulted in a marked increase in the ATP activity measured with Immuknow, and that this increase correlated positively with the number of CD34ϩ cells from peripheral blood. G-CSF and GM-CSF are potent immunomodulatory cytokines, which, in addition to mobilizing hematopoietic stem cells from the bone marrow into peripheral blood, stimulate the production and maturation of phagocytes [35]. In contrast to their powerful effects on myeloid cells, these cytokines appear to exert far fewer effects on lymphocytes.…”

Section: Discussionmentioning

confidence: 99%

Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy

et al. 2009

View full text Add to dashboard Cite

“…GM-CSF exhibits a wide range of effects in macrophages, promoting maturation (44), differentiation (44), cytokine secretion (45), and phagocytosis of opsonized (41) and nonopsonized targets (46). Generation of the GM-CSF-deficient mouse was instrumental in elucidating the role of this cytokine in host defense (44).…”

Section: Discussionmentioning

confidence: 99%

Macrophage Dectin-1 Expression Is Controlled by Leukotriene B4 via a GM-CSF/PU.1 Axis

Serezani

Kane

Collins

et al. 2012

The Journal of Immunology

View full text Add to dashboard Cite

Pattern recognition receptors for fungi include dectin-1 and mannose receptor, and these mediate phagocytosis, as well as production of cytokines, reactive oxygen species, and the lipid mediator leukotriene B4 (LTB4). The influence of G protein-coupled receptor ligands such as LTB4 on fungal pattern recognition receptor expression is unknown. In this study, we investigated the role of LTB4 signaling in dectin-1 expression and responsiveness in macrophages. Genetic and pharmacologic approaches showed that LTB4 production and signaling through its high-affinity G protein-coupled receptor leukotriene B4 receptor 1 (BLT1) direct dectin-1–dependent binding, ingestion, and cytokine production both in vitro and in vivo. Impaired responses to fungal glucans correlated with lower dectin-1 expression in macrophages from leukotriene (LT)- and BLT1-deficent mice than their wild-type counterparts. LTB4 increased the expression of the transcription factor responsible for dectin-1 expression, PU.1, and PU.1 small interfering RNA abolished LTB4-enhanced dectin-1 expression. GM-CSF controls PU.1 expression, and this cytokine was decreased in LT-deficient macrophages. Addition of GM-CSF to LT-deficient cells restored expression of dectin-1 and PU.1, as well as dectin-1 responsiveness. In addition, LTB4 effects on dectin-1, PU.1, and cytokine production were blunted in GM-CSF−/− macrophages. Our results identify LTB4-BLT1 signaling as an unrecognized controller of dectin-1 transcription via GM-CSF and PU.1 that is required for fungi-protective host responses.

show abstract

Granulocyte colony-stimulating factor, granulocyte–macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients

Cited by 13 publications

References 62 publications

Single‐center, real‐world experience with granulocyte colony‐stimulating factor for management of leukopenia following kidney transplantation

Single‐center, real‐world experience with granulocyte colony‐stimulating factor for management of leukopenia following kidney transplantation

Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy

Macrophage Dectin-1 Expression Is Controlled by Leukotriene B4 via a GM-CSF/PU.1 Axis

Contact Info

Product

Resources

About